Published in Arthritis Rheum on March 01, 1988
Cryoglobulins. J Clin Pathol (2002) 1.85
A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J (1990) 1.33
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol (2012) 1.11
Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J (1998) 1.08
Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell (2015) 0.99
Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem J (1996) 0.93
Galactosylation of IgG from rheumatoid arthritis (RA) patients--changes during therapy. Glycoconj J (2006) 0.87
Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. Clin Rheumatol (2004) 0.86
Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord (2010) 0.85
Crystal structure of deglycosylated human IgG4-Fc. Mol Immunol (2014) 0.83
Structural studies on IgG oligosaccharides of patients with primary Sjögren's syndrome. Glycoconj J (2002) 0.82
Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease. J Proteomics (2015) 0.81
The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin Rheumatol (2006) 0.80
Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis. Clin Rheumatol (2010) 0.79
Analysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance. Glycoconj J (2000) 0.78
Role of immunity to mycobacterial stress proteins in rheumatoid arthritis. J Exp Pathol (Oxford) (1990) 0.77
Second Jenner international glycoimmunology meeting. Ann Rheum Dis (1992) 0.77
Glycosylation Profile of IgG in Moderate Kidney Dysfunction. J Am Soc Nephrol (2015) 0.77
Twin studies on the effect of genetic factors on serum agalactosyl immunoglobulin G levels. Biomed Rep (2014) 0.76
A method to identify trace sulfated IgG N-glycans as biomarkers for rheumatoid arthritis. Nat Commun (2017) 0.75
Electric charge and sugar chains of immunoglobulin G in systemic lupus erythematosus. Clin Exp Nephrol (2006) 0.75
Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? Nat Rev Rheumatol (2017) 0.75
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med (1995) 5.18
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87
Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 3.53
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum (1994) 3.15
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
Sociocultural issues in clinical research. Arthritis Rheum (2001) 2.71
The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (1990) 2.59
Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect Immun (1979) 2.57
Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum (1993) 2.49
Biochemical relationship of thymocyte mitogenic factor and factors enhancing humoral and cell-mediated immune responses. J Immunol (1978) 2.28
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem (1987) 2.08
Characterization of the gamma-globulin complexes present in certain sera having high titers of anti-gamma-globulin activity. J Clin Invest (1966) 2.06
An enzymatic method for preparation of dissociated murine Peyer's patch cells enriched for macrophages. J Immunol Methods (1982) 2.06
Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis (1993) 1.98
Clinical characteristics affecting survival in patients with rheumatoid arthritis undergoing cervical spine surgery: a controlled study. J Rheumatol (1989) 1.95
Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum (1989) 1.95
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum (1997) 1.92
Accessory cells in murine Peyer's patch. I. Identification and enrichment of a functional dendritic cell. J Exp Med (1983) 1.92
Radiographic assessment and psychologic variables as predictors of pain and functional impairment in osteoarthritis of the knee or hip. Arthritis Rheum (1988) 1.91
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain (1999) 1.91
Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol (1998) 1.88
Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1985) 1.88
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol (1999) 1.87
Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope) Ann Intern Med (1995) 1.86
Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus (2002) 1.85
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol (1988) 1.80
Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum (1996) 1.77
Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest (1986) 1.70
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Prevention of MIF activity by agents known to increase cellular cyclic AMP. J Immunol (1973) 1.64
A new promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis (1987) 1.62
Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1992) 1.62
Articular involvement in human brucellosis: a retrospective analysis of 304 cases. Semin Arthritis Rheum (1982) 1.62
Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum (1990) 1.61
Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum (1990) 1.59
T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum (1998) 1.55
Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun (2008) 1.53
Perceived physical and emotional trauma as precipitating events in fibromyalgia. Associations with health care seeking and disability status but not pain severity. Arthritis Rheum (1997) 1.51
Methotrexate and sulfasalazine combination therapy: is it worth the risk? Arthritis Rheum (1993) 1.47
Development of clinical criteria for osteoarthritis. J Rheumatol (1987) 1.46
Cyclic adenosine 3',5'-monophosphate in human lung. Biochim Biophys Acta (1971) 1.44
Production of predominantly polymeric IgA by human peripheral blood lymphocytes stimulated in vitro with mitogens. J Exp Med (1980) 1.44
Intraarticular corticosteroid injections: should we rest the joints? Arthritis Care Res (1989) 1.41
Incidence of three cross-reactive idiotypes on human rheumatoid factor paraproteins. J Immunol (1988) 1.39
In vivo immune response to a T-cell-dependent antigen by cultures of disassociated murine Peyer's patch. Proc Natl Acad Sci U S A (1982) 1.39
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis (2007) 1.37
Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum (1998) 1.35
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Human factor D of the alternative complement pathway: purification and characterization. J Immunol (1977) 1.33
Isotype specificity of helper T cell clones. Peyer's patch Th cells preferentially collaborate with mature IgA B cells for IgA responses. J Exp Med (1984) 1.31
Murine Peyer's patch T cell clones. Characterization of antigen-specific helper T cells for immunoglobulin A responses. J Exp Med (1982) 1.30
Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum (1995) 1.28
Global statistical tests for comparing multiple outcomes in rheumatoid arthritis trials. MIRA Trial Group. Arthritis Rheum (1999) 1.27
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
Isolation, characterization and immunolocalization of a 53-kDal dentin sialoprotein (DSP). Matrix (1992) 1.27
Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum (1997) 1.26
Preferential induction of polyclonal IgA secretion by murine Peyer's patch dendritic cell-T cell mixtures. J Exp Med (1984) 1.26
Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol (1995) 1.25
In vitro synthesis of IgM rheumatoid factor by lymphocytes from healthy adults. J Immunol (1980) 1.24
Seronegative rheumatoid arthritis. A distinct immunogenetic disease? Arthritis Rheum (1982) 1.22
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis (2006) 1.20
Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum (1990) 1.20
Immune complexes and other laboratory features of pleural effusions: a comparison of rheumatoid arthritis, systemic lupus erythematosus, and other diseases. Ann Intern Med (1980) 1.19
Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) (2003) 1.19
Early rheumatoid arthritis in African-Americans: the CLEAR Registry. Clin Exp Rheumatol (2004) 1.17
Somatic mutation and CDR3 lengths of immunoglobulin kappa light chains expressed in patients with rheumatoid arthritis and in normal individuals. J Clin Invest (1995) 1.16
Analysis of human IgG and IgA subclass antibody-secreting cells from localized chronic inflammatory tissue. J Immunol (1989) 1.16
Evidence for the identification of lymphocyte activating factor as the adherent cell-derived mediator responsible for enhanced antibody synthesis by nude mouse spleen cells. Cell Immunol (1978) 1.16
International consensus for a definition of disease flare in lupus. Lupus (2010) 1.16
Genetic associations of LYN with systemic lupus erythematosus. Genes Immun (2009) 1.15
Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum (1993) 1.15
Sleep apnea in patients with myasthenia gravis. Neurology (2006) 1.14
Immune complex detection and complement activity in rheumatoid arthritis: a comparative study of a radioimmunoassay using monoclonal rheumatoid factor, gel diffusion techniques and C4 activity. Clin Exp Immunol (1978) 1.12
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis (2010) 1.12
Coping strategies predict disability in patients with primary fibromyalgia. Pain (1996) 1.12
Site of J chain attachment to human polymeric IgA. Proc Natl Acad Sci U S A (1974) 1.12
Airways disease in rheumatoid arthritis patients. One element of a general exocrine dysfunction. Arthritis Rheum (1987) 1.11
Association of a low molecular weight helper factor(s) with thymocyte proliferative activity. J Immunol (1977) 1.11
Sexual and physical abuse in women with fibromyalgia: association with outpatient health care utilization and pain medication usage. Arthritis Care Res (1998) 1.11
The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. Brain (2000) 1.10
A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun (2012) 1.08
Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol (1996) 1.08
Toxicity of methotrexate in rheumatoid arthritis. J Rheumatol (1987) 1.08
Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun (2011) 1.07
Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV). [corrected]. Rheumatology (Oxford) (2008) 1.07
Site of attachment of J chain to human immunoglobulin M. Nature (1974) 1.07
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) (2012) 1.06